1-2 of 2
Tejaswini M. Dhawale
Close
Sort by
Journal Articles

Phase 1 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm

Colin D. Godwin, MDMPhil, Megan Othus, PhD, Mary-Elizabeth M. Percival, MD, Bart L. Scott, MD, Pamela S. Becker, MD PhD, Kelda M. Gardner, PA-C, Sioban B. Keel, MD, Tejaswini M. Dhawale, MD, Vivian G. Oehler, MD, Janis L. Abkowitz, MD, Anna B. Halpern, MD, Paul C. Hendrie, MD PhD, Kaysey F. Orlowski, Alice Woo, Elihu H. Estey, MD, Roland B. Walter, MD PhD MS
Journal: Blood
Blood (2019) 134 (Supplement_1): 3892.
https://doi.org/10.1182/blood-2019-126009
Published: 2019
Journal Articles

The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells

Clinical Trials & Observations
Alexandre V. Hirayama, Jordan Gauthier, Kevin A. Hay, Jenna M. Voutsinas, Qian Wu, Ted Gooley, Daniel Li, Sindhu Cherian, Xueyan Chen, Barbara S. Pender, Reed M. Hawkins, Aesha Vakil, Rachel N. Steinmetz, Utkarsh H. Acharya, Ryan D. Cassaday, Aude G. Chapuis, Tejaswini M. Dhawale, Paul C. Hendrie, Hans-Peter Kiem, Ryan C. Lynch, Jorge Ramos, Mazyar Shadman, Brian G. Till, Stanley R. Riddell, David G. Maloney, Cameron J. Turtle
Journal: Blood
Blood (2019) 133 (17): 1876–1887.
https://doi.org/10.1182/blood-2018-11-887067
Published: 2019
Includes: Supplemental data